N-((5-(2',3',4',5'-tetrafluorophenyl)-1,2,4-oxadiazol-3-yl)methyl)acetamide | 1370025-69-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-((5-(2',3',4',5'-tetrafluorophenyl)-1,2,4-oxadiazol-3-yl)methyl)acetamide
• CAS: 1370025-69-6
• 化学式: C₁₁H₇F₄N₃O₂
• 分子量: 289.189
• InChiKey: UCSSCTXZDLXGRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.93
• 重原子数：
  20.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  68.02
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  吗啉 、 N-((5-(2',3',4',5'-tetrafluorophenyl)-1,2,4-oxadiazol-3-yl)methyl)acetamide 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以84%的产率得到N-((5-(2',3',5'-trifluoro-4'-(morpholin-N'-yl)phenyl)-1,2,4-oxadiazol-3-yl)methyl)acetamide
  参考文献：
  名称：

  Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives

  摘要：

  In the present study the synthesis of new Linezolid-like molecules has been achieved by substitution of the oxazolidinone central heterocyclic moiety with a 1,2,4-oxadiazole ring. Two series of 1,2,4-oxadiazoles, bearing different side-chains and containing a varying number of fluorine atoms, were synthesized and preliminarily tested for biological activity against some Gram-positive and Gram-negative bacteria using Linezolid and Ceftriaxone as reference drugs. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.002
• 作为产物：
  描述：

  反应 0.08h， 以0.5 g的产率得到N-((5-(2',3',4',5'-tetrafluorophenyl)-1,2,4-oxadiazol-3-yl)methyl)acetamide
  参考文献：
  名称：

  Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives

  摘要：

  In the present study the synthesis of new Linezolid-like molecules has been achieved by substitution of the oxazolidinone central heterocyclic moiety with a 1,2,4-oxadiazole ring. Two series of 1,2,4-oxadiazoles, bearing different side-chains and containing a varying number of fluorine atoms, were synthesized and preliminarily tested for biological activity against some Gram-positive and Gram-negative bacteria using Linezolid and Ceftriaxone as reference drugs. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.002